Joseph A. Aloi MD

Dr. Joseph Aloi's early career centered on neuroendocrine responses to pharmacologic challenges in a variety of affective disorders while working as a chemist at the National Institutes of Health. The time spent in the development of trial strategy, conduct of the trial, with subsequent analysis of the data allowed him to develop an expertise in multiple phases of clinical investigation. During his training as a physician at the University of Virginia, Dr. Aloi migrated into the area of reproductive neuro-endocrinology, bridging investigations ranging from rodent models to clinical trial work in women with polycystic ovary syndrome and neuroendocrine function in the geriatric population. He advanced his clinical practice upon becoming a faculty member at the University of Virginia and pursued clinical trials with cardiovascular endpoints for persons with type 2 diabetes – being an investigator in the ADOPT, EXAMINE and EMPA-reg trials. Dr. Aloi transitioned to detection and prevention of type 2 diabetes as Section Chief of Endocrine at the Eastern Virginia Medical School, as experience in these trials convinced him that to impact the growth trajectory of diabetes, it is necessary to prevent diabetes through early detection and lifestyle/pharmacologic intervention. To conduct these efforts efficiently and on a large scale, integrating the clinical assessment with technology, is his current and most important focus as Division of Endocrinology Chief at Wake Forest School of Medicine and current Chair of the American Diabetes Technology Interest Group.